« Back to Record
Citation APA

Loibl, S., Majewski, I. I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., Untch, M., Conte, P., Bernards, R., Piccart-Gebhart, M., von Minckwitz, G., & Baselga, J. (2018). PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Annals of oncology, 29(10), 2151. doi:10.1093/annonc/mdx803


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/283377

Loibl, S., Majewski, I. I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., Untch, M., Conte, P., Bernards, R., Piccart-Gebhart, M., von Minckwitz, G., & Baselga, J. (2018). PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Annals of oncology, 29(10), 2151. doi:10.1093/annonc/mdx803